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Glecaprevir/Pibrentasvir Treatment
in Liver or Kidney Transplant Patients
With Hepatitis C Virus Infection
Nancy Reau ,1 Paul Y. Kwo,2 Susan Rhee,3 Robert S. Brown Jr,4 Kosh Agarwal ,5 Peter Angus,6 Edward Gane,7
Jia-Horng Kao,8 Parvez S. Mantry,9 David Mutimer,10 K. Rajender Reddy ,11 Tram T. Tran,12 Yiran B. Hu,3
Abhishek Gulati,3 Preethi Krishnan,3 Emily O. Dumas,3 Ariel Porcalla,3 Nancy S. Shulman,3 Wei Liu,3 Suvajit Samanta,3
Roger Trinh,3 and Xavier Forns13
Well-tolerated, ribavirin-free, pangenotypic hepatitis C virus (HCV) treatments for transplant recipients remain a
high priority. Once-daily glecaprevir/pibrentasvir demonstrates high rates of sustained virologic response at 12 weeks
posttreatment (SVR12) across all major HCV genotypes (GTs). This trial evaluated the safety and efﬁcacy of glecaprevir/
pibrentasvir for patients with chronic HCV GT1-6 infection who had received a liver or kidney transplant. MAGELLAN-2
was a phase 3, open-label trial conducted in patients who were 3 months posttransplant. Patients without cirrhosis who were
HCV treatment-naive (GT1-6) or treatment-experienced (GT1, 2, 4-6; with interferon-based therapy with or without sofos-
buvir, or sofosbuvir plus ribavirin) received glecaprevir/pibrentasvir (300/120 mg) once daily for 12 weeks. The primary end-
point compared the percentage of patients receiving glecaprevir/pibrentasvir with SVR12 to a historic SVR12 rate based on the
standard of care. Safety of glecaprevir/pibrentasvir was assessed. In total, 80 liver transplant and 20 kidney transplant patients
participated in the trial. Most patients had no or minimal ﬁbrosis (80% had ﬁbrosis scores F0-F1) and were infected with HCV
GT1 (57%) or GT3 (24%). The overall SVR12 was 98% (n/N 5 98/100; 95% conﬁdence interval, 95.3%–100%), which
exceeded the prespeciﬁed historic standard-of-care SVR12 threshold of 94%. One patient experienced virologic failure. One
patient discontinued because of an adverse event considered to be unrelated to treatment; this patient achieved SVR12. Adverse
events were mostly mild in severity, and laboratory abnormalities were infrequent. Conclusion: Once-daily glecaprevir/
pibrentasvir for 12 weeks is a well-tolerated and efﬁcacious, ribavirin-free treatment for patients with chronic HCV GT1-6
infection who have received a liver or kidney transplant. (ClinicalTrials.gov NCT02692703.) (HEPATOLOGY 2018; 00:000-000).
Hepatitis C virus (HCV) infection representsa major global health care challenge thataffects an estimated 177 million people
worldwide.(1) Patients living with chronic HCV infec-
tions are at substantially increased risk of end-stage
liver or kidney disease, necessitating liver and kidney
transplantation. Despite recent advances in HCV
treatments, existing regimens may be complicated by
the addition of ribavirin (RBV), may be limited in
patients with renal impairment, or may not be suitable
for all HCV genotypes (GTs)(2); and more therapeutic
options for transplant patients are needed.
End-stage liver disease caused by chronic HCV infec-
tion is a leading indication for liver transplantation,
accounting for up to 30% of all liver transplants.(3) In
untreated HCV-infected transplant recipients, infection
of the new liver allograft occurs almost universally(4,5) and
is associated with more rapid ﬁbrosis progression, with
Abbreviations: AE, adverse event; CI, conﬁdence interval; DAA, direct-acting antiviral; eGFR, estimated glomerular ﬁltration rate; GT, genotype;
HCV, hepatitis C virus; IFN, interferon; LLOQ, lower limit of quantitation; MedDRA, Medical Dictionary for Regulatory Activities; NS, nonstruc-
tural protein; RBV, ribavirin; SAE, serious AE; SVR, sustained virologic response; SVR12, SVR at 12 weeks posttreatment.
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approximately 30% of untreated transplant recipients
developing cirrhosis within 5 years.(6,7) Following liver
transplantation, the rate of patient and allograft survival
has been lower in HCV-infected recipients compared
with HCV-negative recipients.(8)
Anti-HCV-positive serologic status is also associ-
ated with lower patient and graft survival after kidney
transplantation.(9) Within the kidney transplant popu-
lation, as well as patients who are receiving hemodialy-
sis, the prevalence of HCV infection is approximately
5%-9%.(10-12) In kidney transplant patients, HCV
infection is associated with increased liver-related
mortality and ﬁbrosis progression, and up to 28% of
kidney transplant recipients will die of chronic liver
disease.(13,14) HCV infections in kidney transplant
recipients are also associated with increased rates of
glomerulopathies and risk of cardiovascular death.(15)
Clearance of HCV infection in liver transplant patients
can decrease the risk of HCV-related complications and
improve patient survival.(16) Until recently, treatment
options for HCV were limited to interferon (IFN)-based
therapies, which had low sustained virologic response
(SVR) rates and were poorly tolerated by liver transplant
patients or were contraindicated in kidney transplant
patients.(17) Newer IFN-free, all-oral direct-acting antiviral
(DAA)–based regimens are associated with high rates of
efﬁcacy and tolerability(2) and have demonstrated promising
outcomes in clinical trials and real-world studies in trans-
plant patients.(18-26) However, regimens currently available
for transplant patients are not equally potent across all major
HCVGTs, and some patient subgroups may require RBV
as part of their recommended treatment, which carries a
risk of anemia adverse effects.(2) In addition, currently avail-
able DAAs have the potential for clinically signiﬁcant
drug–drug interactions, particularly with calcineurin inhibi-
tors.(2) Options for kidney transplant patients are especially
limited because of concerns over the use of sofosbuvir and
RBV in patients with severe renal impairment.(27)
The HCV nonstructural protein 3/4A (NS3/4A)
protease inhibitor glecaprevir (formerly ABT-493) and
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the NS5A inhibitor pibrentasvir (formerly ABT-530)
have been developed as a once-daily, all-oral, RBV-
free combination therapy for chronic HCV infection
of all GTs. Both DAAs have shown potent pangeno-
typic antiviral activity in vitro and maintain this activity
against most of the common amino acid substitutions
of HCV GT1-6 that are known to confer resistance to
currently approved inhibitors.(28,29) In phase 2 and 3
clinical trials, treatment with glecaprevir/pibrentasvir
was well tolerated and demonstrated high SVR rates in
patients across all GTs,(30-33) including patients with
compensated cirrhosis and prior treatment failures to
DAA-containing regimens, as well as patients with
severe kidney impairment, with end-stage renal
disease, and undergoing dialysis.(34-36)
In the MAGELLAN-2 study, we evaluated the
safety and efﬁcacy of glecaprevir/pibrentasvir without
RBV for 12 weeks in patients infected with HCV
GT1-6, without cirrhosis, who have undergone liver or
kidney transplantation.
Patients and Methods
PATIENTS AND STUDY DESIGN
MAGELLAN-2 (NCT02692703) was a phase 3,
single-arm, open-label, multicenter trial, conducted to
evaluate the safety and efﬁcacy of glecaprevir/pibren-
tasvir for adult patients with chronic HCV GT1-6
infection, without cirrhosis, who had received primary
liver or kidney transplants. Patients must have had a
positive anti-HCV antibody test and a plasma HCV
RNA viral load 1,000 IU/mL, as well as evidence of
chronic HCV infection, deﬁned as either positive for
anti-HCV antibody or HCV RNA 6 months before
screening, liver biopsy consistent with chronic infec-
tion, or abnormal alanine aminotransferase levels 6
months before screening.
Enrolled patients did not have cirrhosis, as conﬁrmed
by liver biopsy within 6 months prior to screening
(METAVIR, Batts-Ludwig, Knodell, International
Association for the Study of the Liver, Scheuer, or Laen-
nec ﬁbrosis score of 3 or Ishak ﬁbrosis score 4), a
FibroScan (Echosens, Paris, France) score of <12.5 kPa
during or within 3 months of screening, or a FibroTest
(BioPredictive SAS, Paris, France) score of 0.48 and
aspartate aminotransferase-to-platelet ratio index <1 at
screening. Patients could be HCV treatment-naive
(GT1-6) or treatment-experienced (GT1, 2, 4-6), with
treatment experience deﬁned as prior treatment with
IFN, pegylated IFN with or without RBV, or sofosbuvir
plus RBV with or without pegylated IFN that was com-
pleted 2 months before screening. HCV GT3-
infected, treatment-experienced patients were excluded.
Patients had to have received a deceased or living
donor liver or kidney transplant 3 months before
screening and must have been maintained on a stable
immunosuppression regimen based on tacrolimus,
sirolimus, everolimus, mycophenolic acid, azathioprine,
cyclosporine (dosage of 100 mg or less per day), and/or
low-dose steroids (deﬁned as corticosteroids such as
prednisone or prednisolone at dosages of no more than
10 mg per day at the time of screening). Patients were
excluded if they had evidence of hepatitis B virus or
human immunodeﬁciency virus coinfection. Full eligibil-
ity criteria are provided in the Supporting Information.
The trial consisted of a screening period, a 12-week
treatment period, and a 24-week follow-up period
(Fig. 1). Eligible patients received oral glecaprevir/
pibrentasvir 300/120 mg once daily (provided as three
100/40 mg tablets; AbbVie, Chicago, IL). Glecaprevir/
pibrentasvir was to be taken with food at approximately
the same time in the morning every day. Patients took
their concomitant immunosuppression regimens,
titrated per usual care as directed by their physician.
The trial protocol, designed and sponsored by
AbbVie, was approved by the independent ethics com-
mittee or institutional review board for each trial center.
The trial was conducted in accordance with good clini-
cal practice guidelines and the ethical principles of the
Declaration of Helsinki, and all patients provided writ-
ten informed consent. All authors had access to trial
data and reviewed and approved the ﬁnal manuscript.
EFFICACY, SAFETY, AND
RESISTANCE ASSESSMENTS
Plasma samples were collected at screening, at regular
intervals during the trial, and up to 24 weeks following
                                                                 
FIG. 1. MAGELLAN-2 trial design. Patients received 12
weeks of open-label, coformulated, once-daily glecaprevir/pibren-
tasvir 300/120 mg (administered as three tablets of glecaprevir/
pibrentasvir, 100/40 mg each). All patients were followed until
week 36 to monitor for safety and HCV RNA. The primary
endpoint was SVR12.
                                                                 
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the end of treatment for determination of HCV RNA
concentrations. Viral RNA concentrations were mea-
sured at a central laboratory using the COBAS Ampli-
Prep/COBAS TaqMan HCV Quantitative Test, v2.0
(Roche Diagnostics, Indianapolis, IN). The lower limit
of detection and the lower limit of quantitation
(LLOQ) for this assay were both 15 IU/mL.
The primary endpoint was SVR at 12 weeks post-
treatment (SVR12), which was deﬁned as HCV RNA
below the LLOQ 12 weeks after the last dose of glecap-
revir/pibrentasvir. Secondary efﬁcacy endpoints were
the percentages of patients with on-treatment virologic
failure or posttreatment relapse. On-treatment virologic
failure was deﬁned as a conﬁrmed increase in HCV
RNA concentration of >1 log10 IU/mL above nadir
during treatment, conﬁrmed HCV RNA 100 IU/mL
after HCV RNA had fallen below the LLOQ during
treatment, or HCV RNA that exceeded the LLOQ at
the end of treatment for 6 weeks of treatment. Post-
treatment relapse was deﬁned as conﬁrmed HCV RNA
that exceeded the LLOQ between the end of treatment
and 12 weeks after the last dose of glecaprevir/pibren-
tasvir among patients who had completed treatment
with anHCVRNA level below the LLOQ.
Adverse events (AEs) that occurred from initiation of
treatment through 30 days after the last dose of glecapre-
vir/pibrentasvir were monitored and recorded using the
Medical Dictionary for Regulatory Activities (MedDRA)
System Organ Class and preferred term. Severity and
relationship to treatment were assessed by trial investi-
gators. Clinical laboratory tests, physical examinations,
and measurements of vital signs were conducted through-
out the trial. Worsening from baseline during treatment
in laboratory test values was graded using the National
Cancer Institute’s Common Terminology Criteria for
Adverse Events. Plasma samples were collected prior to
dosing on day 1, as well as during the treatment and
follow-up periods for viral RNA isolation andHCV resis-
tance testing. Next-generation sequencing was performed
using samples collected from all patients at baseline.
Presence of HCV baseline polymorphisms in the NS3
and NS5A genes, relative to subtype-speciﬁc reference
sequences, was evaluated using a 15% detection threshold.
For patients who experienced virologic failure, treatment-
emergent substitutions in NS3 and NS5A relative to the
patient’s baseline HCV sequence were analyzed.
Patients recorded their immunosuppressant dosages
in diaries throughout the treatment period, and plasma
samples were also collected locally at screening and at
the following time points during the trial: day 1
(optional); day 3; week 1; day 10; weeks 2, 4, 6, 8, and
12 (or at any time, at the investigators’ discretion) to
monitor cyclosporine, tacrolimus, everolimus, and
sirolimus concentrations.
Treatment adherence data were collected by recording
the total number of tablets dispensed and the total num-
ber of tablets returned. Adherence was calculated as the
percentage of tablets taken relative to the total number of
tablets expected to be taken. A patient was considered
adherent to treatment if the calculated adherence with
the study regimen was between 80% and 120%.
STATISTICAL ANALYSIS
For the primary efﬁcacy endpoint of SVR12, a sam-
ple size of 90 patients was required for this trial to have
>90% power to demonstrate noninferiority to a histori-
cal SVR12 rate of 94% (assuming that 96% of the
patients receiving glecaprevir/pibrentasvir would achieve
SVR12). The historical SVR12 rate was derived from
the SVR rates for the standard of care, 12-week regi-
mens of sofosbuvir/ledipasvir plus RBV or sofosbuvir
plus daclatasvir and RBV in the post–liver transplant
population.(18,22,37) The percentages of patients who
achieved SVR12 were summarized, and a two-sided
95% conﬁdence interval (CI) was calculated using the
normal approximation to the binomial distribution. If
the SVR12 rate was 100%, the Wilson’s score method
would be used to calculate the CI. The lower conﬁdence
bound of the two-sided 95% CI for the percentage of
patients achieving SVR12 must have exceeded 86% to
achieve noninferiority to the standard of care (i.e., a
noninferiority margin of 28%). Patients with missing
data for posttreatment week 12 were counted as SVR12
failures. Efﬁcacy analyses were conducted for the
intention-to-treat population, which comprised all
enrolled patients who received at least one dose of
glecaprevir/pibrentasvir. Analysis of the primary end-
point was also performed for the modiﬁed intention-to-
treat population, deﬁned as the intention-to-treat popu-
lation excluding patients who did not achieve SVR12
for reasons other than virologic failure. Safety analyses
were carried out for all patients who received at least
one dose of glecaprevir/pibrentasvir. Data were analyzed
using SAS (SAS Institute, Inc., Cary, NC).
Results
PATIENTS
A total of 100 patients were enrolled at trial centers
in Australia, Canada, Italy, New Zealand, Puerto
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Rico, Spain, Taiwan, the United Kingdom, and the
United States. All patients received treatment with
glecaprevir/pibrentasvir, and 99 patients completed
treatment. One patient discontinued treatment because
of an AE of cerebrovascular accident that was unre-
lated to glecaprevir/pibrentasvir but achieved SVR12.
Most enrolled patients were male (75%), were white
(78%), and had no or minimal ﬁbrosis (80% had ﬁbro-
sis scores of F0-F1, 14% had a ﬁbrosis score of F3).
All HCV GTs were represented, except GT5 (Table
1). Among the enrolled patients, 80 had received liver
transplants and 20 had received kidney transplants.
Only 11% of patients had normal renal function
(estimated glomerular ﬁltration rate [eGFR] 90 mL/
min/1.73 m2) at baseline (11% of liver transplant
patients; 10% of kidney transplant patients). Overall,
54% of liver transplant patients had an eGFR 60 to
<90 mL/min/1.73 m2, and 55% of kidney transplant
patients had an eGFR <60 mL/min/1.73 m2 (Table
1). Median time since transplantation at baseline was
longer for kidney transplant patients than for liver
transplant patients (132.1 versus 53.8 months, respec-
tively). The most common immunosuppression regi-
men for liver and kidney transplant patients was based
on tacrolimus (68%).
The majority of patients (66%) had received no pre-
vious HCV treatment. Patients who had received prior
HCV treatment had most commonly received an IFN-
based regimen before their liver or kidney transplant.
The most common reasons for prior treatment failure
were breakthrough, on-treatment nonresponse, or
posttreatment relapse.
Baseline polymorphisms were not detected in NS3
at amino acid positions 155, 156, or 168 in any patient,
and were detected in NS5A at amino acid positions
24, 28, 30, 31, 58, 92, or 93 in 33% of patients (see
Supporting Table S1). Two patients with GT1b infec-
tions and 3 patients with GT3a infections had NS5A-
Y93H polymorphisms at baseline.
In total, 99 patients completed 77 days of glecap-
revir/pibrentasvir treatment. Of the 83 patients with
available adherence data, 82 (99%) were >80% adher-
ent to therapy.
EFFICACY
For the primary efﬁcacy endpoint, 98% of patients
treated with glecaprevir/pibrentasvir achieved SVR12
(n/N 5 98/100; 95% CI, 95.3%-100%) by the
intention-to-treat analysis (Fig. 2). The lower bound
of the 95% CI was >86%, indicating noninferiority to
the standard of care. For the secondary endpoints, no
patients had on-treatment virologic failure. Two
patients were designated as SVR12 nonresponders: 1
patient had virologic failure (relapse by posttreatment
week 4) and 1 patient had nonvirologic failure as a
result of missing SVR12 data. By modiﬁed intention-
to-treat analysis, which excluded patients who failed to
achieve SVR12 for nonvirologic reasons, the SVR12
rate was 99% (n/N 5 98/99; 95% CI, 97%-100%).
SVR12 rates for patient subgroups are provided in the
Supporting Information.
The 1 patient who experienced virologic relapse had
a treatment duration of 88 days and was 97.7% adher-
ent to glecaprevir/pibrentasvir treatment. This patient
had GT3a infection, was HCV treatment-naive, had
F0-F1 ﬁbrosis, had a baseline HCV RNA level of 7.56
log10 IU/mL, and had received a liver transplant. The
patient had no baseline polymorphisms in NS3 and
had the treatment-emergent substitution Y56H at the
time of failure. The Y93H polymorphism in NS5A
was detected at baseline and at the time of failure. Gle-
caprevir and pibrentasvir plasma concentrations were
within the proposed therapeutic range throughout the
treatment period (not shown).
SAFETY
Overall, 85 patients (85%) experienced AEs (Table
2). The most commonly experienced AEs were fatigue
(22%), headache (22%), nausea (12%), pruritus (12%),
and diarrhea (10%). AEs for the majority of patients
(56%) were mild.
Eight patients experienced serious AEs (SAEs; see
Supporting Table S3), 2 of which were considered to be
related to glecaprevir/pibrentasvir (sinusitis and
abnormal hepatic function [MedDRA preferred
terms]). One patient experienced an SAE of cerebrovas-
cular accident, which was not considered to be related to
glecaprevir/pibrentasvir therapy, that led to treatment
discontinuation on day 50. This patient achieved
SVR12. No other patients experienced AEs that led to
treatment discontinuation, and there were no deaths.
One liver transplant patient experienced a non-SAE
of transplant rejection (conﬁrmed by biopsy). This AE
was mild (grade 1), managed by titration of the patient’s
immunosuppression regimen (everolimus and tacroli-
mus), and resolved after 9 days. Glecaprevir/pibrentas-
vir was continued without interruption, and the patient
achieved SVR12. No kidney transplant patients experi-
enced AEs related to transplant rejection.
HEPATOLOGY, Vol. 00, No. 00, 2018 REAU ET AL.
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Six patients (6%) experienced worsening of labora-
tory values during treatment, relative to baseline, that
were grade 3 or 4 in severity (Table 3): 1 patient had a
single grade 3 alanine aminotransferase value on day 3,
which steadily declined while on treatment and nor-
malized; 1 patient had total bilirubin and creatinine
elevations to grade 3 on days 43 and 46 (attributed to a
drug interaction between concomitant medications









Female 16 (20) 9 (45) 25 (25)
Male 64 (80) 11 (55) 75 (75)
Race, n (%)
White 67 (84) 11 (55) 78 (78)
Black or African American 1 (1) 7 (35) 8 (8)
Asian 8 (10) 2 (10) 10 (10)
Other* 4 (5) 0 4 (4)
Age (years), median (range) 61 (42-78) 56 (39-70) 60 (39-78)
Body mass index (kg/m2), mean (SD) 27.5 (5.0) 27.3 (6.7) 27.4 (5.3)
HCV genotype, n (%)
1a 22 (28) 6 (30) 28 (28)
1b 18 (23) 11 (55) 29 (29)
2 13 (16) 0 13 (13)
3 22 (28) 2 (10) 24 (24)
4 3 (4) 1 (5) 4 (4)
5 0 0 0
6 2 (3) 0 2 (2)
HCV RNA 6 3 106 IU/mL, n (%) 27 (34) 4 (20) 31 (31)
IL28B non-CC genotype, n (%) 45 (56) 13 (65) 58 (58)
Baseline fibrosis stage, n (%)
F0-F1 62 (78) 18 (90) 80 (80)
F2 6 (8) 0 6 (6)
F3 12 (15) 2 (10) 14 (14)
Baseline eGFR (mL/min/1.73 m2), n (%)
<60 28 (35) 11 (55) 39 (39)
60 to <90 43 (54) 7 (35) 50 (50)
90 9 (11) 2 (10) 11 (11)
Platelet count 90 3 109/L, n (%) 76 (95) 20 (100) 96 (96)
Albumin 35 g/L, n (%) 78 (98) 19 (95) 97 (97)
Time since transplantation (months), median (range) 53.8 (4.2-213.7) 132.1 (4.6-545.3) 55.6 (4.2-545.3)
Immunosuppressant medication, n (%)
Cyclosporine 9 (11) 4 (20) 13 (13)
Tacrolimus 57 (71) 11 (55) 68 (68)
Other† 14 (18) 5 (25) 19 (19)
HCV treatment experience, n (%) 30 (38) 4 (20) 34 (34)
IFN-based 28 (35) 4 (20) 32 (32)
Sofosbuvir-based 1 (1) 0 1 (1)
Other 1 (1) 0 1 (1)
Pretransplant HCV treatment experience, n (%) 21 (26) 3 (15) 24 (24)
Posttransplant HCV treatment experience, n (%) 9 (11) 1 (5) 10 (10)
Response to previous HCV treatment, n (%)
Breakthrough/nonresponder 13 (16) 2 (10) 15 (15)
Posttreatment relapse 10 (13) 1 (5) 11 (11)
Unknown or other 7 (9) 1 (5) 8 (8)
*“Other” category includes Native American or Alaska native, native Hawaiian or other Paciﬁc Islander, and multiple races.
†“Other” category includes azathioprine, everolimus, mycophenolic acid, prednisolone, prednisone, and sirolimus.
Abbreviations: IL, interleukin; SD, standard deviation.
REAU ET AL. HEPATOLOGY, Month 2018
6
tacrolimus and clarithromycin and not related to gle-
caprevir/pibrentasvir); 1 patient on anticoagulant ther-
apy had grade 3 international normalized ratio values
on days 8, 11, 43, and 57; 1 patient had a single grade
3 platelet value on day 8 and a grade 3 international
normalized ratio (international normalized ratio value
was the result of incorrect recording in the patient
database); 1 patient had a grade 3 creatinine elevation
on day 87, grade 3 reductions in creatinine clearance
on days 4, 8, 29, 43, and 85, and a grade 4 reduction
in creatinine clearance on day 87; 1 patient had grade 3
reductions in creatinine clearance on days 5 and 8. The
creatinine or creatinine clearance changes were attrib-
utable to ongoing diagnosis of urinary tract infections
in both patients.
IMMUNOSUPPRESSANT DOSING
At any given study visit, a minority of patients had
either an increase or a decrease in the dosage of their
immunosuppressant medication, without any consis-
tent pattern associated with study drug dosing (see
Supporting Table S4). Overall, the median total daily
doses of cyclosporine (100 mg/day), everolimus (1.25
mg/day), and sirolimus (1.00 mg/day) were unchanged
throughout the duration of the trial (Fig. 3). The
median total daily tacrolimus dose decreased from 2.75
to 2.00 mg/day between baseline and day 7 but re-
mained unchanged through the remainder of the trial.
                                                                 
FIG. 2. Rates of SVR12 following treatment for all patients
who received at least one dose of glecaprevir/pibrentasvir. For the
overall intention-to-treat and modiﬁed intention-to-treat analy-
ses, 95% CIs were calculated using the normal approximation to
the binomial distribution or the Wilson’s score method for rates
of 100%. For separate intention-to-treat analyses of liver and kid-
ney transplant patients, 95% CIs were calculated using the Wil-
son’s score method. Abbreviations: ITT, intention-to-treat;
LTFU, lost to follow-up; mITT, modiﬁed intention-to-treat
(excluding patients with nonvirologic failure).
                                                                 




Any AE 85 (85)
Any AE possibly related to DAAs 48 (48)
Any AE with grade 3 severity or greater 12 (12)
Any DAA-related AE with grade 3 severity or greater 3 (3)
Any SAE 8 (8)
Any SAE possibly related to DAAs 2 (2)
Any AE leading to treatment discontinuation 1 (1)
Death 0






*MedDRA version 19.1 was used for reporting of AEs.




Platelets (<50 3 109/L) 1 (1)
INR (>2.5 3 ULN) 1 (1)
Alanine aminotransferase (>5 3 ULN) 1 (1)
Total bilirubin (>3 3 ULN) 1 (1)
Creatinine clearance (<30 mL/min) 2 (2)
*Numbers and percentages of patients who experienced grade 3
or 4 (Common Terminology Criteria for Adverse Events) wors-
ening of laboratory values from baseline are shown.
Abbreviations: INR, international normalized ratio; ULN, upper
limit of normal.
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Discussion
The MAGELLAN-2 trial was conducted to evalu-
ate the efﬁcacy and safety of 12 weeks of glecaprevir/
pibrentasvir without RBV for patients without cirrho-
sis but with HCV GT1-6 infections who had received
liver or kidney transplants. In this trial, liver or kidney
transplant patients, most of whom had no or minimal
ﬁbrosis, achieved an SVR12 rate of 98%, demonstrat-
ing noninferiority of glecaprevir/pibrentasvir to the
historic standard of care. The efﬁcacy of glecaprevir/
pibrentasvir was unaffected by patients’ baseline char-
acteristics, HCV GT, baseline polymorphisms in NS3
and/or NS5A, or previous hepatitis C treatment expe-
rience. Outside of the transplant setting, similarly high
SVR12 rates have been demonstrated in HCV-
infected patients with minimal ﬁbrosis treated with
glecaprevir/pibrentasvir.(31,32)
A single patient experienced virologic failure in the
MAGELLAN-2 trial. This patient had minimal
ﬁbrosis, was adherent to therapy, and had glecaprevir
and pibrentasvir exposures within the therapeutic
ranges. The patient had a treatment-emergent substi-
tution Y56H in NS3 at the time of failure, and Y93H
in NS5A was detected at baseline and at the time of
failure. Given the low number (n 5 3) of GT3-
infected patients with baseline NS5A-Y93H in the
trial population, conclusions on the potential impact of
this polymorphism on efﬁcacy cannot be made. How-
ever, in an integrated analysis of glecaprevir/pibrentas-
vir phase 2 and 3 clinical trials, this polymorphism had
no impact on treatment outcome.(38) In addition,
100% (n/N 5 5/5) of GT3-infected patients with
baseline Y93H polymorphisms achieved SVR12 fol-
lowing 8 weeks of treatment with glecaprevir/pibren-
tasvir in the ENDURANCE-3 trial.(33)
Once-daily glecaprevir/pibrentasvir was well toler-
ated. The majority of AEs were mild and consistent
with those reported in previous studies of glecaprevir/
pibrentasvir.(32,33) No patients discontinued because of
treatment-related AEs, and there were few SAEs
attributed to glecaprevir/pibrentasvir. Laboratory ab-
normalities of grade 3 or higher were infrequent. The
overall safety proﬁle for patients treated with glecapre-
vir/pibrentasvir in the MAGELLAN-2 trial was gen-
erally consistent with the safety proﬁle expected for
transplant patients and reﬂective of the underlying
medical conditions of this population.
Interactions with concomitant immunosuppression
regimens are a particular concern for posttransplant
patients. In the current trial, median dosages of tacroli-
mus were slightly reduced within the ﬁrst week of
treatment but remained unchanged for the remainder
of the treatment period. Adjustments to immunosup-
pressant dosages have been reported(18,22) and may be
attributable to improving liver function and increased
immunosuppressant metabolism.(18) There were no
overall changes to median dosages of cyclosporine,
sirolimus, or everolimus. No clinically relevant safety
ﬁndings were identiﬁed and attributed to a potential
drug interaction between glecaprevir/pibrentasvir and
any of the coadministered immunosuppressants.
The joint HCV treatment guidelines of the American
Association for the Study of Liver Diseases and the
Infectious Diseases Society of America were updated in
2017 to recommend combination therapy with glecap-
revir/pibrentasvir for 12 weeks for the treatment of
chronic HCV GT1-6 infections in liver transplant
patients without cirrhosis on the basis of the results of
the MAGELLAN-2 trial.(2) Ledipasvir/sofosbuvir plus
RBV for 12 weeks (GT1, 4, 5, and 6) and daclatasvir/
sofosbuvir plus RBV for 12 weeks (GT2 and 3) are rec-
ommended for liver transplant patients without cirrhosis
or with compensated cirrhosis.(2) In the phase 2, open-
label SOLAR-1 trial, treatment with ledipasvir/sofosbu-
vir plus RBV for 12 or 24 weeks resulted in SVR12
rates of 96%-98% in a broad spectrum of liver transplant
patients with GT1 infections.(18) In the phase 3, open-
label ALLY-1 trial, daclatasvir/sofosbuvir plus RBV for
12 weeks resulted in SVR12 rates of 95% for liver trans-
plant patients with GT1 infections and 91% for patients
with GT3 infections.(22) However, these studies were
                                                                 
FIG. 3. Immunosuppressant dosing from baseline to end of
treatment for liver and kidney transplant patients. Median dos-
ages of everolimus (closed circles), sirolimus (closed diamonds),
and tacrolimus (closed squares) are plotted using the left y-axis;
median dosages of cyclosporine (closed triangles) are plotted
using the right y-axis. Abbreviation: BL, baseline.
                                                                 
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limited by the inclusion of very low numbers of patients
with non-GT1 infections. By contrast, enrollment of
GT1 patients was limited to approximately 50% of the
MAGELLAN-2 trial population in order to enrich the
trial with patients with non-GT1 infections. In addi-
tion, currently recommended DAA regimens are com-
plicated by the addition of weight-based RBV dosing
and the requirement to monitor for RBV-associated
AEs (particularly RBV-induced anemia),(2) whereas 12
weeks of treatment with glecaprevir/pibrentasvir
achieved high SVR12 rates in the absence of RBV. The
efﬁcacy and safety proﬁles of glecaprevir/pibrentasvir
also raise the possibility of reducing waitlist times for
patients requiring transplants, by increasing the size of
the pool of available organs to include those from
HCV-infected donors.
MAGELLAN-2 represents the ﬁrst trial of a pange-
notypic DAA regimen to achieve SVR12 rates at or
approaching 100% across multiple genotypes in kidney
transplant patients. Based on these ﬁndings, the updated
American Association for the Study of Liver Diseases/
Infectious Diseases Society of America guidelines recom-
mend glecaprevir/pibrentasvir for 12 weeks for kidney
transplant patients with HCV GT1-6 infections. Ledi-
pasvir/sofosbuvir treatment for 12 weeks is also recom-
mended for kidney transplant patients with GT1 or GT4
infections. In a randomized, phase 2, open-label trial, 12
or 24 weeks of ledipasvir/sofosbuvir treatment resulted in
100% SVR12 for kidney transplant patients with GT1 or
GT4 infections without cirrhosis or with compensated
cirrhosis.(23) However, a number of patients treated with
ledipasvir/sofosbuvir experienced decreased eGFR values
during treatment.(23)
A limitation of the MAGELLAN-2 trial was that
patients with cirrhosis and those who previously failed
DAA therapy were excluded from the study, popula-
tions that may require a longer duration of therapy. In
addition, patients with a history of ﬁbrosing cholestatic
hepatitis or coinfection with human immunodeﬁciency
virus were excluded from the trial.
Glecaprevir/pibrentasvir is a pangenotypic, 12-week,
RBV-free treatment option for transplant patients
without cirrhosis that demonstrates high efﬁcacy, a
favorable safety proﬁle, and minimal interaction with
concomitant immunosuppression regimens.
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